A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma-Reference-Cited by-同舟云学术

A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

Published:2018-04 Issue:3 Volume:41 Page:151-157
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Robertson Michael J.,Stamatkin Christopher W.,Pelloso David,Weisenbach Jill,Prasad Nagendra K.,Safa Ahmad R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference57 articles.

1. Coherent view of non-Hodgkin’s lymphoma;Aisenberg;J Clin Oncol,1995

2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;Philip;N Engl J Med,1995

3. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission;Vose;Biol Blood Marrow Transplant,2004

4. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease;Yuen;Blood,1997

5. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 trial;Ferme;J Clin Oncol,2002

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner;Molecular Therapy;2024-07

2. Synthetic Cells and Molecules in Cellular Immunotherapy;International Journal of Biological Sciences;2024

3. Bioengineering strategies to enhance the interleukin-18 bioactivity in the modern toolbox of cancer immunotherapy;Cytokine & Growth Factor Reviews;2023-09

4. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition;mAbs;2023-07-19

5. Cancer Immunotherapy Beyond Checkpoint Blockade;JACC: CardioOncology;2022-12